This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Jensen, Donald
| Item Type | Name |
|
Concept
|
Hepatitis C, Chronic
|
|
Concept
|
Hepatitis B, Chronic
|
|
Academic Article
|
Sticker shock and the price of new therapies for hepatitis C: is it worth it?
|
|
Academic Article
|
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
|
|
Academic Article
|
Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.
|
|
Academic Article
|
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
|
|
Academic Article
|
Retreatment of chronic hepatitis C in previous non-responders and relapsers.
|
|
Academic Article
|
Future directions in therapy for chronic hepatitis C.
|
|
Academic Article
|
Ribavirin in the treatment of chronic hepatitis C.
|
|
Academic Article
|
Hepatitis C: current and future therapies.
|
|
Academic Article
|
Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report.
|
|
Academic Article
|
Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure.
|
|
Academic Article
|
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
|
|
Academic Article
|
A new era of hepatitis C therapy begins.
|
|
Academic Article
|
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
|
|
Academic Article
|
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
|
|
Academic Article
|
IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?
|
|
Academic Article
|
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.
|
|
Academic Article
|
Future therapies for chronic hepatitis C.
|
|
Academic Article
|
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
|
|
Academic Article
|
The FDA, bridging data, and hepatitis C.
|
|
Academic Article
|
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
|
|
Academic Article
|
Human immunodeficiency virus and coinfection with hepatitis B and C.
|
|
Academic Article
|
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
|
|
Academic Article
|
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
|
|
Academic Article
|
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
|
|
Academic Article
|
Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer.
|
|
Academic Article
|
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
|
|
Academic Article
|
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
|